23 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Many of the drugs covered by…
1 June 2020The potential to cause ankle oedema appears to exist for all calcium channel blocking agents, and is caused by increasing capillary pressure leading to leakage…
1 June 2020Ankle oedema is a common, often troublesome adverse effect for patients who are receiving calcium channel blocker (CCB) therapy, and may affect compliance. It is…
Medicine Compliance Aid Stability
ZanidipRecordati Pharmceuticals Ltd
Recordati Pharmceuticals Ltd
Tablets f/c 10mg, 20mg
A3 · Amber 3 No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
If put into an MCA it should be opaque and protected from light, moisture and heat.
9 November 2015
Lactation Safety Information
No published evidence of safety
Monitor infant for adverse effects
3 August 2020